Ann: Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers, page-16

Although this data was produced outside of a living organism, the pre-clinical data looks promising.

ARG-007 has already demonstrated no adversary side effects in phase 1 clinical trial dosing, although we're yet to see the effectiveness of the drug on patients rather than subjects. could we correlate the phase 1 data on ARG-007's stroke trials with the effectiveness of ARG-007 on upcoming alzheimer trials on living organisms? They're the same drug, the only underlying potential data which couldn't be correlated (correct me if I'm wrong), is the reaction and effectiveness on the patients of the aforementioned stroke or alzheimers.

cheers